ClinicalTrials.gg
RecruitingNCT03388775DVTUpdated Mar 12, 2025

Real World Study of Deep Venous Thrombosis. Analysis of Prospective Cases in University Hospitals of São Paulo

An observational study in Registry, sponsored by Fundação Faculdade Regional de Medicina de São José do Rio Preto. Recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Fundação Faculdade Regional de Medicina de São José do Rio Preto · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2013; still recruiting 13 years 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 31 studies in Venous Thrombosis with a site in Brazil — 4 open to participants now, 4 under way, none of them phase 3. Venous Thrombosis · Brazil.

Started
2013
with 1 other
Observational
4 of 31
1 open now
Registered
25th of 31
by date
Lead sponsor
1 of 31
Fundação Faculdade Regional de Medicina de São José do Rio Preto

Among the 31 studies in Venous Thrombosis with a site in Brazil, this one is one of 2 that started in 2013, is one of 4 observational ones, and was the 25th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

4 of the 31 studies in Venous Thrombosis with a site in Brazil are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Venous Thrombosis with a site in Brazil, or all of them as a file.
02

Study summary

Background: Deep venous thrombosis (DVT) is a common and important vascular disease due to its morbidity and mortality.

Its incidence remains high throughout the world and constitutes serious problems for national and international public health.

Several inherited and/or acquired risk factors may be responsible for thrombus formation. Few epidemiological data regarding real world panorama of this disease in South America and Brazil is available in the literature.

Objective: Evaluate demographic data, diagnostic methods and treatment of deep vein thrombosis in the real world in public university hospitals in Brazil.

Methods: Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.

Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications. Digital platform has been used in data collection. Is a multicenter study and analysis will be performed using Microsoft Excel and Epi-Info.

Key words: deep vein thrombosis, assessment, risk factors, demographic data.

Read the detailed description

Introduction DVT is a multidisciplinary disease, mainly as consequence of surgical or clinical conditions, and the acute pulmonary embolism and the post-thrombotic syndrome (PTS) are the most serious complications.

The incidence of deep venous thrombosis of the lower limbs in the population is from 0.2 to 0.7 cases per 1,000 inhabitants/year and in Brazil an estimated incidence of 0.6 cases/1000 inhabitants/year has been estimated.

Risk factors for DVT include: advanced age, history of immobilization or prolonged bed rest during hospitalization, obesity, smoking, recent surgery, previous VTE episodes, cancer, major or lower limb trauma, cancer therapy, acute infectious disease, heart failure, respiratory insufficiency, contraceptive use or hormone replacement therapy, pregnancy or postpartum, stroke with motor deficit, family history of VTE (thrombophilia).

The clinical diagnosis of DVT, based on physical examination only, is imprecise and insensitive and only one-third or less of the clinical suspicions are confirmed by imaging tests.

The primary goals of DVT treatment are to prevent and / or treat their complications. Anticoagulant therapy is efficacious but associated to some risk of bleeding. Mechanical prophylactic measures (ambulation and use of elastic stockings with gradual compression) are important in high risk patients and in cases with contraindication of anticoagulants.

Although well known, epidemiological data on this disease may have some particularities related to geographic regions. Data from registries in USA and Europe has shown some differences in demographic profile, risk factors and treatments.

Few epidemiological data regarding real world panorama of this disease in South America and Brazil is available in the literature.

So, the objective of this was to evaluate demographic data, diagnostic methods and and treatment of deep vein thrombosis in the real world in public university hospitals in Brazil.

Methods

  1. Population of patients The Registries of the Universities Hospitals (RHEUNI) in Brazil have been registry consecutive patients with deep venous thrombosis that was started on July 2013, with a prospective collection of epidemiological data of patients referred to five public university hospitals in the state of São Paulo (Base Hospital of São José do Rio Preto Medical School , Clinics Hospital Ribeirão Preto Medical School of São Paulo University, Clinics Hospital of Campinas University, Clinics Hospital of Botucatu Medical School of the Paulista State University, Clinics Hospital of Marília Medical School). This study was approved in the ethics committees of all institutions. An informed consent form was signed by the patient after explaining the purpose of the study.

    Inclusion criteria are as follows: patients with venous thrombosis in any site, male or female, regardless of age, with first episode or recurrent episodes and with or without pulmonary embolism.

    There are no exclusion criteria.

  2. Patients registration Patients has been performed in planned digital spreadsheets and loaded in a computer program for statistical analysis (Epi-Info). Every single completed worksheets will be exported to Excel worksheet for statistical analysis.

    The main outcomes to be reviewed are: demographic characteristics (age, sex and color), main risk factors for DVT and time of clinical history collected from consecutive patients referred for those Hospitals. The main symptoms and signs reported by patients, the sectors affected by thrombosis, as well as the diagnostic tools employed were registered.

  3. Worksheet form The recorded characteristics and backgrounds of patients with venous thrombosis include: age, gender, and main clinics or surgical risk factors. In addition, the main signs and symptoms and the sectors affected by thrombosis will be reported, and the diagnostic tools employed.

    The use of various anticoagulants for the treatment of venous thrombosis and complications related mainly to bleeding will be analyzed.

  4. Responsibilities of researchers and institutions The principal investigators and co-participants are committed to maintain the project along time with accurate information and to participate in quarterly meetings of the RHEUNI group to analyze the progress of the project and to publish the results.

    The project has no external financial support and there is no conflicts of interest of any researcher.

  5. Statistical analysis The analyzes will include the sociodemographic characteristics of patients with deep venous thrombosis. The projected number of cases during the study period is approximately 800 patients. All analyzes will be conducted using Microsoft Excel.

The objective of the study is to evaluate the demographic data and the most common clinical characteristics of patients with deep venous thrombosis in public hospitals, their main predisposing factors, the most commonly used diagnostic tests and the treatments performed. The participating hospitals have common characteristics: they are large public university hospitals with a significant number of patients hospitalized and trained by new angiologists and vascular surgeons in the Sao Paulo State. This study will represent a significant sample of deep venous thrombosis and its main risk factors and treatments performed so that this disease can be prevented in some hospital and post-discharge situations in an attempt to reduce its incidence. Treatment in our real world in most cases is not possible to be performed outpatient initially due to socio-economic conditions of patients and difficulty in acquiring the new oral anticoagulants.

03

Conditions studied

  • Registry

Browse trials for

Keywords

  • deep vein thrombosis
  • assessment
  • risk factors
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with venous thrombosis in any site, male or female, regardless of age, with first episode or recurrent episodes and with or without pulmonar embolism.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with venous thrombosis in any site, male or female, regardless of age, with first episode or recurrent episodes and with or without pulmonary embolism.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Patients with deep venous thrombosis

    Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo. Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications.

    Other: deep venous thrombosis

Interventions

  • Otherdeep venous thrombosis

    Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.

06

What researchers measure

Primary outcomes

  1. Incidence of risk factors for DVT

    1. Inheriting a blood-clotting disorder. 2. Prolonged bed rest, such as during a long hospital stay, or paralysis. 3. Injury or surgery. 4. Pregnancy. 5. Birth control pills (oral contraceptives) or hormone replacement therapy. 6. Being overweight or obese. 7. Smoking. 8. Cancer. 9. Heart failure. 10. Inflammatory bowel disease. 11. A personal or family history of deep vein thrombosis or pulmonary embolism. 12. Age. Being older than 60 increases your risk of DVT.

    Time frame: Five Years

Secondary outcomes

  1. Types of treatment performed in the real world

    Anticoagulation. Types of treatment performed in the real world Description: Anticoagulation. * Unfractionated heparin, which is given into a vein (intravenously) - This may be the preferred choice in certain circumstances, such as if the patient has severe kidney failure or unstable blood pressure. * Direct oral anticoagulants - These are available in pill form; they include rivaroxaban (brand name: Xarelto) and apixaban (brand name: Eliquis). The choice of anticoagulant depends upon multiple factors, including the preference of the patient and the healthcare provider, the patient's medical history and other conditions, and cost considerations.

    Time frame: Five Years

07

Study locations

1 of 1 sites recruiting
  • Clinics Hospital of Faculty of Medicine of Paulista State University
    Botucatu, São Paulo 18607621, Brazil
    Recruiting
    • Winston B Yoshida, MD; PhD · Contactjvascbr.ed@gmail.com · 55 14 38116269
    • Marcone L Sobreira, MD; PhD · Contactmlsobreira@gmail.com · 55 14 38116269
    • Winston B Yoshida, MD; PhD · Sub investigator
    • Marcone L Sobreira, MD; PhD · Sub investigator
    • Regina Moura, MD; PhD · Sub investigator
    • Edwaldo E Jovilliano, MD; PhD · Sub investigator
    • Ana T Guillaumon, MD; PhD · Sub investigator
    • Marcelo J Almeida, MD; PhD · Sub investigator
    • Daniel G Miquelin · Sub investigator
    • Ludvig Hafner · Sub investigator
    • Martin A Geiger · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2013 (actual). Primary completion is estimated for Dec 2025, 149 months after the start.

Of 103 non-industry observational studies under Venous Thrombosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 99. This study's planned 149 months is above that.

Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2017
First posted
Jan 3, 2018
StartActual
Jul 2013
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03388775
Lead sponsor
Fundação Faculdade Regional de Medicina de São José do Rio Preto
Collaborators
University of Ribeirao Preto
Responsible party
Selma Regina de Oliveira Raymundo (Principal Investigator, Fundação Faculdade Regional de Medicina de São José do Rio Preto) — Principal investigator
First posted
Jan 3, 2018
Start date
Jul 2013
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 12, 2025

Study contacts

Selma R Raymundo, MD; PhD
Contact
selma_ray@terra.com.br
55 17 996016062
Edwaldo E Joviliano, MD; PhD
Contact
eejovilliano@gmail.com
55 16 36021000 ext. 2406
Selma R Raymundo, MD; PhD
principal investigator · Fundação Faculdade Regional de Medicina de São Jose Do Rio Preto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion